The Cigna Group stock: RBC raises target to $346
Published on 11/20/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRBC sharpens its Cigna view
- RBC Capital kept its Outperform rating while lifting its price target to 346 US dollars.
- The analyst cited stronger Cigna Healthcare performance and continued momentum in Specialty and Care Services.
- Pharmacy Benefit Services headwinds and the company's ACA exchange exit remain important considerations for the outlook.
RBC Capital raised its price target for The Cigna Group to 346 US dollars from 337 US dollars on Thursday, November 19, while maintaining an Outperform rating. Markets Insider reported that the analyst action followed stronger-than-expected performance at Cigna Healthcare and continued momentum in Specialty and Care Services.
Healthcare strength supports target
RBC's assessment linked the latest earnings beat to Cigna Healthcare's performance. The analyst also pointed to momentum in Specialty and Care Services, giving the research note a more constructive view of the operating backdrop.
Pharmacy risks remain relevant
Anticipated headwinds at Pharmacy Benefit Services partly offset the positive operating picture. The company has also exited the Affordable Care Act exchange market, a strategic change that affects the basis for future earnings comparisons.
Management raised its full-year guidance and expressed confidence in at least 10 percent adjusted earnings-per-share growth from a 30 US dollar run-rate base adjusted for the ACA exchange exit. RBC's note nevertheless keeps pharmacy trends and the 2027 execution path central to the investment case.
Current quote and investor context
The Cigna Group stock last traded at 253.25 euros on Lang & Schwarz at 15:33 CET on Friday, November 20, 2026.
The Cigna Group at a glance
- Company: The Cigna Group
- ISIN: US1255231003
- Quote: 253.25 euros on Lang & Schwarz, November 20, 2026, 15:33 CET
- Analyst action: RBC Capital target raised to 346 US dollars from 337 US dollars; Outperform maintained
The US healthcare market remains an important backdrop for the sector. Current market reports provide broader market context.
